PURPOSE: To report a cluster of high incidence of noninfectious inflammatory reaction shortly after bevacizumab injection. METHODS: Data were collected from medical records of consecutive patients who underwent bevacizumab injections and presented with acute uveitis within 1-4 days. RESULTS: All 7 patients were injected intravitreally with bevacizumab from different batches and presented with visual deterioration. One patient with anterior uveitis complained of pain. None had hypopyon. Three patients with vitritis underwent a vitreous tap with an intravitreal injection of vancomycin and ceftazidime for possible infectious endophthalmitis. All patients received intensive topical antibiotic drops and steroids, and the intraocular inflammation resolved completely within 1 month. Five patients continued to receive bevacizumab injections without recurrent episodes. CONCLUSIONS: Our series demonstrates an incidence of noninfectious inflammatory reaction shortly after bevacizumab injection that is higher than that reported in the literature. The cause is more likely the preparation process in the same compounding pharmacy.
PURPOSE: To report a cluster of high incidence of noninfectious inflammatory reaction shortly after bevacizumab injection. METHODS: Data were collected from medical records of consecutive patients who underwent bevacizumab injections and presented with acute uveitis within 1-4 days. RESULTS: All 7 patients were injected intravitreally with bevacizumab from different batches and presented with visual deterioration. One patient with anterior uveitis complained of pain. None had hypopyon. Three patients with vitritis underwent a vitreous tap with an intravitreal injection of vancomycin and ceftazidime for possible infectious endophthalmitis. All patients received intensive topical antibiotic drops and steroids, and the intraocular inflammation resolved completely within 1 month. Five patients continued to receive bevacizumab injections without recurrent episodes. CONCLUSIONS: Our series demonstrates an incidence of noninfectious inflammatory reaction shortly after bevacizumab injection that is higher than that reported in the literature. The cause is more likely the preparation process in the same compounding pharmacy.
Authors: Rebecca E H Whiting; Jacqueline W Pearce; Daniella P Vansteenkiste; Katherine Bibi; Stefanie Lim; Grace Robinson Kick; Leilani J Castaner; John Sinclair; Sundeep Chandra; Annalisa Nguyen; Charles A O'Neill; Martin L Katz Journal: Exp Eye Res Date: 2020-07-01 Impact factor: 3.467
Authors: Ramin Khoramnia; Marta S Figueroa; Lars-Olof Hattenbach; Carlos E Pavesio; Majid Anderesi; Robert Schmouder; Yu Chen; Marc D de Smet Journal: Graefes Arch Clin Exp Ophthalmol Date: 2021-12-21 Impact factor: 3.535